David Mauney

David Mauney, MD

Managing Director, Koch Disruptive Technologies (KDT)
Board Observer

David is a Managing Director at Koch Disruptive Technologies (KDT), where he leads KDT’s investment efforts across the major sectors in the healthcare arena.

David has over 25 years of experience in healthcare operations, fundraising, and investing. Prior to KDT, David worked at several healthcare venture financed companies, as well as serving as co-founder and Managing Director of two venture capital entities.  He co-founded De Novo Ventures, a life science venture capital firm that managed more than $700 million across three funds with a combined portfolio of over 70 companies.  He was also a co-founder and Managing Director of the Harvest Intrexon Enterprise Fund, a $245 million fund focused on tools that edit biological systems.  David also served as President of the publicly traded biopharmaceutical company Ziopharm Oncology.

David holds a BA from Duke University and an MD from Dartmouth School of Medicine. In his free time David enjoys spending time with his family, traveling, golfing, and doing other outdoor activities.

Bitterroot Bio is a privately held company dedicated to the pursuit of breakthroughs in cardiovascular medicine. We are committed to improving the lives of patients, and we believe that focusing on research and development is the best way to achieve that goal. We do not engage in, support, or advocate on behalf of political, social, environmental, or other causes that are unrelated to our mission.
Scroll to Top